December 17, 2024 - 11:30

In a powerful address to representatives of Italian banks, Pope Francis condemned the detrimental effects of certain financial practices, highlighting issues such as offshoring, resource displacement, and speculation. He emphasized that these practices often prioritize profit over the well-being of individuals and communities, leading to a system that "tramples on people."
The Pope's remarks come amid growing concerns about the impact of financial systems on the most vulnerable populations. He called for a reevaluation of current economic practices and renewed his calls for debt relief, urging financial institutions to adopt more ethical approaches that prioritize social responsibility.
Pope Francis reiterated the importance of fostering a financial environment that supports human dignity and promotes sustainable development. He urged bankers to reflect on their role in society and to consider how their decisions affect the lives of ordinary people, advocating for a shift towards a more compassionate and equitable financial system.
March 28, 2026 - 08:16
Upstate woman charged with insurance fraud and financial identity theftAn Upstate woman has been arrested and charged with insurance fraud and financial identity theft following an investigation into a suspicious vehicle damage claim. According to arrest warrants, the...
March 27, 2026 - 21:27
Social Media Giants Face Market Pressure Following Legal SetbackShares of major social media companies extended their losses on Friday, as investors continued to digest the financial and regulatory implications of a recent legal defeat. The sell-off reflects...
March 27, 2026 - 00:26
NDSU College of Business launches Center for Banking and FinanceA new hub dedicated to the financial sector has officially opened its doors, aiming to bridge the gap between academic theory and real-world practice. The recently launched Center for Banking and...
March 26, 2026 - 05:08
Precigen Reports Full Year 2025 Financial Results and Business UpdatesPrecigen, Inc. has officially transitioned into a commercial-stage biotechnology company, marking a transformative year in 2025. This shift follows the landmark US approval of PAPZIMEOS™...